IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: S. Kalled and H. Reid)
Application No.: 10/505,376) Group Art Unit: 1649) Examiner: D. Kolker
Filed: July 1, 2005)))
For: USE OF BCMA AS AN IMMUNOREGULATORY AGENT) Confirmation No.: 2363

Mail Stop Petition

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)

The above-identified application became abandoned for failure to file a timely and proper response to the Office action mailed on January 23, 2009, which set a three-month period for response. The abandonment date of this application is April 24, 2009 (i.e., the day after the expiration date of the three-month period set for response). The entire delay in filing the required reply, from the due date for the required reply until the filing of a grantable petition under 37 C.F.R. § 1.137(b), was unintentional, as demonstrated below.

Applicant hereby petitions for revival of this application. The petition fee of \$1,620.00 is enclosed. In addition, Applicant submits a response to the above-noted

Application No.: 10/505,376

Office action in the form of a divisional application. Because this application was filed on or after June 8, 1995, no terminal disclaimer is required.

Remarks

The above-identified application is assigned to Biogen Inc. (Biogen) and LaTrobe University (LaTrobe). Certain subject matter disclosed and originally claimed in the application, namely, antibodies to BAFF ligand, is exclusively licensed to Glaxo SmithKline (GSK) and Human Genome Sciences (HGS) (collectively "GSK/HGS"). A restriction requirement issued on November 19, 2008, requiring restriction among various aspects of the claimed subject matter, including antibodies to BAFF ligand. In response to the restriction requirement, the claims were amended so as to no longer claim antibodies to BAFF ligand. A first substantive office action was issued on January 23, 2009. On instructions from Biogen in-house counsel dated July 8, 2009, no response to this office action was filed. The application thus became abandoned.

Neither GSK/HGS nor LaTrobe intended to abandon the application, and Biogen's in-house counsel did not intend to deprive GSK/HGS of any rights in the BAFF ligand antibody subject matter. Upon learning of the abandonment of the application on November 18, 2009, GSK/HGS contacted Biogen in-house counsel on November 19, 2009 to investigate the circumstances of the abandonment and determine possible remedies, leading to the filing of this petition and the accompanying divisional application (U.S. Application No. 12/862,448, filed August 24, 2010, courtesy copy of e-filing receipt attached) claiming the BAFF ligand antibody technology. All of the delay involved in filing this petition for revival was unintentional.

If there are any additional fees due in connection with the filing of this Petition, the Commissioner is authorized to charge such fees to Deposit Account 06-0916.

Respectfully submitted,

Dated: August 24, 2010

Leslie A. McDonell Reg. No. 34,872

08201.0028-00000

Application No.: 10/505,376

Attachment

Courtesy Copy of e-filing receipt for U.S. Application No. 12/862,448, filed August 24, 2010.

Electronic Acknowledgement Receipt		
EFS ID:	8282230	
Application Number:	12862448	
International Application Number:		
Confirmation Number:	4026	
Title of Invention:	USE OF BCMA AS AN IMMUNOREGULATORY AGENT	
First Named Inventor/Applicant Name:	Susan L. Kalled	
Customer Number:	65779	
Filer:	Leslie A. McDonell/Carol Karuzis	
Filer Authorized By:	Leslie A. McDonell	
Attorney Docket Number:	08201.0028-01000	
Receipt Date:	24-AUG-2010	
Filing Date:		
Time Stamp:	17:09:40	
Application Type:	Utility under 35 USC 111(a)	

Payment information:

Submitted with Payment	no
Submitted man ayment	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		application.PDF	2623854	yes	66
	аррисацоп. г д	c2c66f55d0a1fe71970b940eb041d3c5c6d bffb4	1		

	Multip	oart Description/PDF files in	.zip description		
	Document Description		Start	End	
	Specification		1	48	
	Claims		49	52	
	Abstract		53	5:	53
	Drawings-only black and white line drawings		54	66	
Warnings:					
Information:					
2	2 Miscellaneous Incoming Letter	sequence_statement.pdf	35627	no	1
	miscentificous meoning certei		00fea0c5f84c3ccbeb3399380deaf31916e0 0858		,
Warnings:					
Information:					
3	Sequence Listing	sequence_listing.PDF	129177	no	5
-	5 Sequence Listing		ba5a8eeb6c4420ae699b7c97c7a2ca1add9 c335d		
Warnings:					
Information:					
4	Transmittal of New Application	Transmittal.pdf	94538	no	2
	·	31c61859c31f0759f717e06d0e23f010b925 a000			
Warnings:	44.400.000		And the second s	······································	
Information:	- Hydron or				
-		declaration_POA.pdf	165038	no	2
5 Oath	Oath or Declaration filed		54779d86498c6e51ead6775a7a3dd5d304 78b180	no	
Warnings:					
Information:					
		Total Files Size (in bytes	3048	8234	